Interleukin-34 and Disease Activity in Systemic Lupus Erythematosus Patients
DOI:
https://doi.org/10.24293/ijcpml.v27i2.1636Keywords:
Systemic lupus erythematosus, interleukin-34, SLEDAI, Mex-SLEDAIAbstract
Systemic Lupus Erythematosus (SLE) is characterized by exacerbation and remission, which needs close monitoring of the disease activity. Systemic lupus erythematosus disease activity can be determined by the SLE Disease Activity Index (SLEDAI) score. Evaluation of the disease activity is essential to be a guidance for treatment. Interleukin-34 (IL-34) is related to the pathogenesis of SLE. Serum IL-34 can be a candidate marker to evaluate SLE disease activity, and it is correlated with the SLEDAI score. This study aimed to determine the correlation between IL-34 level and disease activity in SLE patients based on the SLEDAI (Mex-SLEDAI) score. An observational analytical study with a cross-sectional design was carried out in six months (June-November 2019) in 27 SLE patients in the Department of Internal Medicine, Faculty of Medicine, Sumatera Utara University/Adam Malik General Hospital, Medan. Systemic lupus erythematosus disease activity was measured based on the Mex-SLEDAI score. Serum and urine were collected to obtain the Mex-SLEDAI score and IL-34 level. IL-34 level was measured in all subjects by using Enzyme-Linked Immunosorbent Assay (ELISA). Spearman correlation test was used to
determine the correlation between IL-34 level and disease activity in SLE patients based on the SLEDAI (Mex-SLEDAI) score. There was a significant correlation between IL-34 level and disease activity in SLE patients based on SLEDAI (Mex-SLEDAI) score (r=0.965, p < 0.001). Further studies were needed with a sample of SLE patients in a balanced proportion based on their disease activity to obtain representative IL-34 levels in SLE patients based on their disease activity.
Downloads
References
Xie HH, Shen H, Zhang L, Cui MY, Xia LP, Lu J. Elevated serum interleukin-34 level in patients with systemic lupus erythematosus is associated with disease activity. Sci Rep, 2018; 8(1): 3462.
Baghdadi M, Umeyama Y, Hama N, Kobayashi T, Han N, Wada H, et al. Interleukin-34, a comprehensive review. Journal of Leukocyte Biology, 2018; 104: 931–51.
Guillonneau C, Bézie S, Aegon I. Immunoregulatory properties of the cytokine IL-34. Cell Mol Life Sci, 2017; 74(14): 2569-86.
Kementerian Kesehatan Republik Indonesia. Infodatin situasi lupus di Indonesia 2017 [Internet]. 2017; 8. Available from:www.depkes.go.id/resources/download/pusdatin/infodatin/Infodatin-Lupus
-2017.pdf (accessed 2 February, 2019).
Kasjmir YI, Handono K, Wijaya LK, Hamijoyo L, Albar Z, Kalim H, et al. Rekomendasi Perhimpunan
Reumatologi Indonesia untuk diagnosis dan pengelolaan lupus eritematosus sistemik. Jakarta,
Perhimpunan Reumatologi Indonesia, 2011; 1–54.
Y. Santamaria-Alza, JD. Sanchez-Bautiista, J. Fajardo-Rivero CLF-P. Comparison of disease activity
scores predicting mortality in patients with systemic lupus erythematosus in Columbia. BMJ, 2019; 1090:
-1090.
Wang H, Cao J, Lai X. Serum interleukin-34 levels are elevated in patients with systemic lupus erythematosus. Molecules, 2017; 22(1): 35.
Wallace DJ, Hahn BH. Dubois'lupus erythematosus and related syndromes. Ninth Ed., Sydney, Elsevier Inc, 2019; 772.
Saleh AM, Kurniati N, Syarif BH. Penilaian aktivitas penyakit lupus eritematosus sistemik dengan skor
SLEDAI di Departemen Ilmu Kesehatan Anak RSCM. Sari Pediatr, 2016; 16(4): 292.
Atkinson JP, Yu CY. The complement system in systemic lupus erythematosus. In: Systemic lupus
erythematosus: Basic, applied, and clinical aspects. USA, Elsevier Inc, 2016; 81–112.
Finzel S, Schaffer S, Rizzi M, Voll RE. Pathogenesis of systemic lupus erythematosus. Zeitschrift fur
Rheumatologie, 2018; 77: 789–98.
Adamichou C, Bertsias G. Flares in systemic lupus erythematosus: Diagnosis, risk factors, and preventive strategies. Mediterranean Journal of Rheumatology, 2017; 28(1): 4–12.
Baghdadi M, Endo H, Tanaka Y, Wada H, Ichiro SK. Interleukin 34, from pathogenesis to clinical
applications [Internet]. Cytokine. Elsevier, 2017; 99: 139–47. Available from: http://dx.doi.org/10.1016/
j.cyto.2017.08.020 (accessed 2 February, 2019).
Masteller EL, Wong BR. Targeting IL-34 in chronic inflammation. Drug Discov today [Internet]. 2014;
(8): 1212–6. Available from: http://dx.doi.org/10.1016/j.drudis.2014.05.016 (accessed 2 February,
.
Ge Y, Huang M, Yao YM. Immunomodulation of interleukin-34 and its potential significance as a
disease biomarker and therapeutic target. International Journal of Biological Sciences, 2019; 15: 1835–45.
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.